{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:13:23Z","timestamp":1791357203137,"version":"4.3.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,2,13]],"date-time":"2014-02-13T00:00:00Z","timestamp":1392249600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s11916-014-0408-5","type":"journal-article","created":{"date-parts":[[2014,2,12]],"date-time":"2014-02-12T08:31:09Z","timestamp":1392193869000},"source":"Crossref","is-referenced-by-count":5,"title":["Emerging Therapies for Chronic Migraine"],"prefix":"10.1007","volume":"18","author":[{"given":"Alberto","family":"Proietti Cecchini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licia","family":"Grazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,13]]},"reference":[{"issue":"1","key":"408_CR1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11916-010-0157-z","volume":"15","author":"N Aubrey","year":"2011","unstructured":"Aubrey N, Manack AN, Buse DC, Lipton RB. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep. 2011;15(1):70\u20138.","journal-title":"Curr Pain Headache Rep"},{"issue":"4","key":"408_CR2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/head.12047","volume":"53","author":"E Schulman","year":"2013","unstructured":"Schulman E. Refractory migraine - a review. Headache. 2013;53(4):599\u2013613.","journal-title":"Headache"},{"issue":"9","key":"408_CR3","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/j.1526-4610.2010.01764.x","volume":"50","author":"SD Silberstein","year":"2010","unstructured":"Silberstein SD, Dodick DW, Pearlman S. Defining the pharmacologically intractable headache for clinical trials and clinical practice. Headache. 2010;50(9):1499\u2013506.","journal-title":"Headache"},{"key":"408_CR4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11916-011-0231-1","volume":"16","author":"G Coppola","year":"2012","unstructured":"Coppola G, Schoenen J. Cortical excitability in chronic migraine. Curr Pain Headache Rep. 2012;16:93\u2013100.","journal-title":"Curr Pain Headache Rep"},{"issue":"8","key":"408_CR5","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1177\/0333102413477739","volume":"33","author":"D Magis","year":"2013","unstructured":"Magis D, Vigano A, Sava S, D'Elia TS, Schoenen J, Coppola G. Pearls and pitfalls: electrophysiology for primary headaches. Cephalalgia. 2013;33(8):526\u201339.","journal-title":"Cephalalgia"},{"key":"408_CR6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1526-4610.2012.02274.x","volume":"53","author":"SE Lakhan","year":"2013","unstructured":"Lakhan SE, Avramut M, Tepper SJ. Structural and functional neuroimaging in migraine: insights from 3 decades of research. Headache. 2013;53:46\u201366.","journal-title":"Headache"},{"key":"408_CR7","first-page":"115","volume":"4","author":"JA Picaza","year":"1975","unstructured":"Picaza JA, Cannon BW, Hunter SE, et al. Pain suppression by peripheral nerve stimulation. Part II. Observations with implanted devices. Surg Neurol. 1975;4:115\u201326.","journal-title":"Surg Neurol"},{"issue":"3","key":"408_CR8","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1302\/0301-620X.67B3.2987272","volume":"67","author":"H Waisbrod","year":"1985","unstructured":"Waisbrod H, Panhans C, Hansen D, Gerbershagen HU. Direct nerve stimulation forpainful peripheral neuropathies. J Bone Joint Surg Br. 1985;67(3):470\u20132.","journal-title":"J Bone Joint Surg Br"},{"issue":"3","key":"408_CR9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1525-1403.1999.00217.x","volume":"2","author":"RL Weiner","year":"1999","unstructured":"Weiner RL, Reed KL. Peripheral neurostimulation for control of intractable occipital neuralgia. Neuromodulation. 1999;2(3):217\u201321.","journal-title":"Neuromodulation"},{"key":"408_CR10","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrn3057","volume":"12","author":"S Akerman","year":"2011","unstructured":"Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011;12:570\u201384.","journal-title":"Nat Rev Neurosci"},{"key":"408_CR11","doi-asserted-by":"crossref","unstructured":"Magis D, Schoenen J. Advances and challenges in neurostimulation for headaches. Lancet Neurol. 2012;11(8), 708\u201319. This paper provides an exhaustive and updated review of various central and peripheral neuromodulation modalities for treatment of severe intractable primary headache.","DOI":"10.1016\/S1474-4422(12)70139-4"},{"issue":"suppl 1","key":"408_CR12","first-page":"30 (abstract)","volume":"29","author":"R Lipton","year":"2009","unstructured":"Lipton R, Goadsby PJ, Cady R, et al. PRISM study: occipital nerve stimulation for treatment refractory migraine. Cephalalgia. 2009;29 suppl 1:30 (abstract).","journal-title":"Cephalalgia"},{"issue":"3","key":"408_CR13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/0333102410381142","volume":"31","author":"JR Saper","year":"2011","unstructured":"Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ, et al. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia. 2011;31(3):271\u201385.","journal-title":"Cephalalgia"},{"issue":"16","key":"408_CR14","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0333102412462642","volume":"32","author":"SD Silberstein","year":"2012","unstructured":"Silberstein SD, Dodick DW, Saper J, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2012;32(16):1165\u201379.","journal-title":"Cephalalgia"},{"issue":"14","key":"408_CR15","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/0333102413489040","volume":"33","author":"JL Pedersen","year":"2013","unstructured":"Pedersen JL, Barloese M, Jensen RH. Neurostimulation in cluster headache: a review of current progress. Cephalalgia. 2013;33(14):1179\u201393.","journal-title":"Cephalalgia"},{"issue":"Pt 1","key":"408_CR16","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/brain\/awh022","volume":"127","author":"MS Matharu","year":"2004","unstructured":"Matharu MS, Bartsch T, Ward N, et al. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain. 2004;127(Pt 1):220\u201330.","journal-title":"Brain"},{"key":"408_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1525-1403.2011.00425.x","volume":"15","author":"RM Levy","year":"2012","unstructured":"Levy RM. The conflict of safety versus access to new therapies: the FDA, clinical trial design and neuromodulation. Neuromodulation. 2012;15:1\u20134.","journal-title":"Neuromodulation"},{"issue":"64","key":"408_CR18","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ana.21427","volume":"2008","author":"D Ranoux","year":"2008","unstructured":"Ranoux D, Attal N, Morain F, Bouhasira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;2008(64):274\u201383.","journal-title":"Ann Neurol"},{"key":"408_CR19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1526-4610.2005.05066.x","volume":"45","author":"N Mathew","year":"2005","unstructured":"Mathew N, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache. A randomized, double blind, placebo controlled trial. Headache. 2005;45:293\u2013307.","journal-title":"Headache"},{"key":"408_CR20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10194-011-0339-z","volume":"12","author":"G Sandrini","year":"2011","unstructured":"Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G, et al. Botulinum toxin type-A in the prophylaxis treatment of medication-overuse headache: a multi center, double blind, randomized, placebo-controlled, parallel group study. J Head Pain. 2011;12:427\u201333.","journal-title":"J Head Pain"},{"key":"408_CR21","unstructured":"BOTOX 100 units: UK summary of product characteristics. Available at: http:\/\/www.medicines.org.uk\/EMC\/medicine\/112\/SPC\/BOTOX+100+units\/ [Accessed 2011 Nov 1]."},{"key":"408_CR22","unstructured":"Vistabel: UK summary of product characteristics [online]. Available at: http:\/\/www.medicines.org.uk\/EMC\/medicine\/17580\/SPC\/Vistabel\/ [Accessed 2011 Nov 16]."},{"key":"408_CR23","unstructured":"BOTOX (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use: US prescribing information. Available at: http:\/\/www.allergan.com\/assets\/pdf\/botox_pi.pdf [Accessed 2011 Nov 2]."},{"key":"408_CR24","unstructured":"BOTOX\u00ae Cosmetic (onabotulinumtoxinA) for injection: US prescribing information. Available at: http:\/\/www.allergan.com\/assets\/pdf\/botox_cosmetic_pi.pdf [Accessed 2011 Nov 16]."},{"key":"408_CR25","unstructured":"BOTOX 200 units: UK summary of product characteristics. Available at: http:\/\/www.medicines.org.uk\/EMC\/medicine\/22562\/SPC\/Botox+200+units\/[Accessed 2011 Nov 1]."},{"key":"408_CR26","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1526-4610.2010.01766.x","volume":"50","author":"A Blumenfeld","year":"2010","unstructured":"Blumenfeld A, Silberstein S, Dodick D, Aurora S, Turkel C, Binder W. Method of injection of Onabotulinum toxin A for Chronic Migraine: a safe, well-tolerated and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50:1406\u201318.","journal-title":"Headache"},{"issue":"11","key":"408_CR27","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0968-0004(02)02177-1","volume":"27","author":"K Turton","year":"2002","unstructured":"Turton K, Chaddock JA, Acharya KR. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci. 2002;27(11):552\u20138.","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"408_CR28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/0974-2077.41148","volume":"1","author":"U Wollina","year":"2008","unstructured":"Wollina U. Botulinum toxin: non-cosmetic indications and possible mechanisms of action. J Cutan Aesthet Surg. 2008;1(1):3\u20136.","journal-title":"J Cutan Aesthet Surg"},{"issue":"5","key":"408_CR29","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neuro.2005.01.017","volume":"26","author":"KR Aoki","year":"2005","unstructured":"Aoki KR. Review of a proposed mechanism for the anti-nociceptive action of botulinum toxin type A. Neurotoxicol. 2005;26(5):785\u201393.","journal-title":"Neurotoxicol"},{"issue":"10","key":"408_CR30","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/j.1526-4610.2011.02022.x","volume":"51","author":"PL Durham","year":"2011","unstructured":"Durham PL, Cady R. Insights into the mechanism of ona-botulinumtoxinA in chronic migraine. Headache. 2011;51(10):1573\u20137.","journal-title":"Headache"},{"key":"408_CR31","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neuro.2005.01.017","volume":"26","author":"KR Aoki","year":"2005","unstructured":"Aoki KR. Review of a proposed mechanisms for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005;26:785\u201393.","journal-title":"Neurotoxicology"},{"issue":"Suppl","key":"408_CR32","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1046\/j.1526-4610.43.7s.3.x","volume":"43","author":"KR Aoki","year":"2003","unstructured":"Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003;43(Suppl):S9\u2013S15.","journal-title":"Headache"},{"key":"408_CR33","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pain.2008.10.005","volume":"141","author":"P Gazerani","year":"2009","unstructured":"Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L. Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009;141:60\u20139.","journal-title":"Pain"},{"issue":"6","key":"408_CR34","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2165\/11208880-000000000-00000","volume":"72","author":"J Frampton","year":"2012","unstructured":"Frampton J. Onabotulinumtoxin A (BOTOX). A review of its use in the prophlylaxis of Headaches in adults with Chronic Migraine. DRUGS. 2012;72(6):625\u201345.","journal-title":"DRUGS"},{"key":"408_CR35","unstructured":"Allergan. A study using botulinum toxin type A as headache prophylaxis for migraine patients with frequent headaches [ClinicalTrials.gov identifier NCT00156910]. US National Institutes of Health, ClinicalTrials.gov. Available at: http:\/\/clinicaltrials.gov [Accessed 2011 Nov 2]."},{"key":"408_CR36","unstructured":"Allergan. A study using botulinum toxin type A as headache prophylaxis for migraine patients with frequent headaches [ClinicalTrials.gov identifier NCT00168428]. US National Institutes of Health, ClinicalTrials.gov. Available at: http:\/\/clinicaltrials.gov [Accessed 2011 Nov 2]."},{"issue":"4","key":"408_CR37","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1526-4610.2005.05066.x","volume":"45","author":"NT Mathew","year":"2005","unstructured":"Mathew NT, Frishberg BM, Gawel M, et al. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache. 2005;45(4):293\u2013307.","journal-title":"Headache"},{"issue":"9","key":"408_CR38","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.4065\/80.9.1126","volume":"80","author":"SD Silberstein","year":"2008","unstructured":"Silberstein SD, Stark SR, Lucas SM. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2008;80(9):1126\u201337.","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"408_CR39","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1111\/j.1526-4610.2009.01566.x","volume":"49","author":"NT Mathew","year":"2009","unstructured":"Mathew NT, Jaffri SFA. A double-blind comparison of onabotulinumtoxinA (BOTOX) and topiramate (TOPA-MAX) for the prophylactic treatment of chronic migraine: a pilot study. Headache. 2009;49(10):1466\u201378.","journal-title":"Headache"},{"issue":"1","key":"408_CR40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1526-4610.2010.01796.x","volume":"51","author":"RK Cady","year":"2011","unstructured":"Cady RK, Schreiber CP, Porter JAH, et al. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache. 2011;51(1):21\u201332.","journal-title":"Headache"},{"key":"408_CR41","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1526-4610.2011.01990.x","volume":"51","author":"SK Aurora","year":"2011","unstructured":"Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51:1358\u201373.","journal-title":"Headache"},{"issue":"15","key":"408_CR42","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1177\/0333102411420585","volume":"31","author":"CP Yang","year":"2011","unstructured":"Yang CP, Chang MH, Liu PE, et al. Acupuncture versus topiramate in chronic migraine prophylaxis: a randomized clinical trial. Cephalalgia. 2011;31(15):1510\u201321.","journal-title":"Cephalalgia"},{"key":"408_CR43","doi-asserted-by":"crossref","unstructured":"Colloca L, Klinger R, Flor H, Bingel U. Placebo analgesia: psychological and neurobiological mechanisms. Pain. 2013 Apr;154(4):511\u20134. Placebo effect is not that demon and we should learn how to maximize it in clinical use in the meantime that scientists will work out its role in RCTs.","DOI":"10.1016\/j.pain.2013.02.002"},{"key":"408_CR44","unstructured":"Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. Available at: http:\/\/guidance.nice.org.uk\/ta260 . Accessed June 2012."}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-014-0408-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11916-014-0408-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-014-0408-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T15:03:36Z","timestamp":1565190216000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11916-014-0408-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,13]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["408"],"URL":"https:\/\/doi.org\/10.1007\/s11916-014-0408-5","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,13]]},"article-number":"408"}}